The “hand tearing” Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) incident of Wang Sicong, the son of former richest man Wang Jianlin, continued to ferment.
On April 14, Wang Sicong shouted on his microblog: “the CSRC should strictly investigate Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) “! On April 15, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) share price fell by the limit, and the market value evaporated by 6.7 billion.
On the afternoon of April 16, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) relevant person in charge responded to the media that the company had never said on any occasion that the WHO recommended Lianhua Qingwen. Earlier, the company’s Board Secretary responded on the interactive exchange that “if necessary, he will safeguard his legitimate rights and interests through legal means”.
Since the mid-term report of 2020, the natural person shareholder named Ma Yun has also appeared in the ranks of Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) top ten shareholders. As of the end of the third quarter of last year, Ma Yun held a total of 7.3731 million shares, with the latest market value of 265 million yuan after the limit fell on the 15th. Is Ma Yun the founder of Alibaba Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) responded that “the company does not have the relevant details of Mr. Ali Ma Yun”p align=”center” style=”text-align:left;”> Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) respond positively again
Since April 5, there have been media articles “who recognizes the efficacy of traditional Chinese medicine in the treatment of covid-19”, and even “Lianhua Qingwen has obtained a reliable basis for prevention and treatment”. On April 6, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) with Lianhua Qingwen opened sharply higher than the limit, and then Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) rose another 20% within three trading days from April 7 to 11. Since the beginning of the year, the share price has doubled.
At this time, on the afternoon of April 14, Wang Sicong, the “chairman of Beijing price capital and director of Wanda Group” with 40 million fans, suddenly “got into trouble”, forwarded a message about Lianhua Qingwen on his microblog, and commented that “the CSRC should strictly investigate Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) “. Wang Sicong forwarded a video entitled “bedtime editorial department” on the microblog, entitled “who recommended” Lianhua Qingwen, who told you? “, The owner said he “repeatedly questioned the efficacy and marketing model of Lianhua Qingwen”.
Wang Sicong’s forwarding and comments attracted widespread attention. About one hour after forwarding, Wang Sicong re edited the above microblog and deleted the contents such as “CSRC should strictly investigate Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) “, but still retained the content of the above forwarding.
On the day the above microblog came out, it did not have a significant impact on Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) stock price. However, with the fermentation of public opinion, the next day, that is, April 15, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) opened sharply lower and killed. It fell to the limit for the first time more than half an hour later. After more than two hours of “struggle”, it finally fell to the limit, and the market value evaporated 6.7 billion.
On the afternoon of April 16, according to China Entrepreneur Magazine, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) responded positively to Wang Sicong’s query. ” Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) relevant person in charge” stated to “Chinese entrepreneur”: “the company has never said on any occasion that ‘who recommends Lianhua Qingwen'”. “The above person in charge explained that what the who recognizes is the efficacy of traditional Chinese medicine including Lianhua Qingwen for covid-19 pneumonia.”
Earlier, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) Secretary of the board of directors said in an interactive and easy answer to investors’ questions, “we believe that” those who are clear will be clear “about the untrue statements on the Internet, and will continue to track the development of the situation, and will safeguard their legitimate rights and interests through legal means when necessary”p align=”center” style=”text-align:left;”> who recommends Lianhua Qingwen? No
Does the who recommend Lianhua Qingwen for covid-19 control? The answer is: really not!
The Fund found the original WHO Expert Meeting on Evaluation of traditional Chinese medicine in the treatment of covid-19 on the official website of who, and the article was published on March 31. (link: https://www.who.int/publications/m/item/who-expert-meeting-on-evaluation-of-traditional-chinese-medicine-in-the-treatment-of-covid-19 )。
This article is similar to the summary of a seminar. From February 28 to March 2, 2022, who experts held a meeting to “evaluate” the use of traditional Chinese medicine in covid-19 treatment. It mentioned some “main findings”: for example, “the traditional Chinese medicine studied is useful in the treatment of covid-19 (especially mild and moderate cases)” “the data show that traditional Chinese medicine is useful in reducing the evolution of mild and moderate cases to severe cases”, and so on.
However, in the 17 page text, there is no mention of “Lianhua Qingwen”, let alone the so-called “recommendation”. The whole report “Lianhuaqingwen” appeared only twice, both in the cited literature and the same paper of the same author.
So, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) did he say “who recommends Lianhua Qingwen”? From the public information, there is No.
The public reports on this matter on the Internet mainly appeared on April 5, including the news broadcast of China Central Television, which reported on the WHO seminar, but the contents were “who recognizes the efficacy of traditional Chinese medicine in the treatment of covid-19” and “encourages Member States to consider its application”, and did not explicitly mention Lianhua Qingwen.
However, after that, many articles suddenly linked “who approved traditional Chinese medicine” with Lianhua Qingwen, For example, “recognized by who! Lianhua Qingwen contributes” Chinese wisdom “to global campaigns”, “Chinese patent medicine is recognized by who, and Lianhua Qingwen contributes” Chinese wisdom “to global campaigns”, “who confirms that Chinese patent medicine can effectively treat covid-19! Research shows that symptoms disappear faster after taking Lianhua Qingwen”, etc. Many netizens questioned that these articles are suspected of marketing.
Ma Yun’s lying gun “lost” 30 million
Interestingly, Alibaba founder Jack Ma is also involved in “disputes”.
Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) past financial reports show that since the mid-term report of 2020, the natural person shareholder named “Ma Yun” appeared in the ranks of Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) top ten shareholders for the first time, with an initial shareholding ratio of 0.38%.
Since then, Ma Yun has been among the top ten shareholders of Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) and has increased his position. In the first quarter and the third quarter of 2021, Ma Yun increased his holdings of Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) 433900 shares and 2329700 shares respectively.
By the end of the third quarter of 2021, Ma Yun held Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) 737373731 million shares, with a shareholding ratio of 0.44%, and was the seventh largest shareholder. According to the stock price of 35.99 yuan after Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) falling on April 15, the above shares are still worth 265 million yuan, but the market value is close to 300 million before falling. Some netizens ridiculed that Wang Sicong’s microblog made Ma Yun lose 30 million. However, calculated from the price range when Ma Yun bought, his floating profit is still far more than 100 million.
Some investors asked on the interactive platform “is Ma Yun, a natural person shareholder among the top ten shareholders, Alibaba’s Ma Yun?”. In response, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) responded that “the company does not have the relevant details of Mr. Ali Ma Yun”.
According to the data of China stock market news, the “Ma Yun” holds a total of shares of two companies, namely Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) and Huayi Brothers Media Corporation(300027) , holding 0.44% and 3.59% respectively. According to the analysis of some netizens, the probability of being able to spend hundreds of millions of funds and having the same name is not high. The probability of “Ma Yun” is the well-known Ma Yun.
\u3000
